# Keros Therapeutics (KROS) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/KROS
## Company Profile
- Ticker: KROS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 10.65 USD
- Market cap: 208803880.35000002 USD
- Last updated: 2026-08-06
## Business Overview
### TGF-β Biology Platform
Keros Therapeutics develops protein therapeutics for diseases linked to dysfunctional signaling within the transforming growth factor-beta family, which regulates muscle, bone, adipose tissue, cardiac tissue, and blood-cell development.
### Rinvatercept
Rinvatercept is the company’s lead internally controlled candidate and is being developed for Duchenne muscular dystrophy and amyotrophic lateral sclerosis.
### Elritercept Partnership
Elritercept targets cytopenias, including anemia and thrombocytopenia, in myelodysplastic syndromes and myelofibrosis. Takeda has assumed development responsibility under a licensing partnership.
## Why The Stock Is Moving

As of Aug 6, 2026, KROS closed up 6.55% at $10.65. No new same-company headline was identified in the current news window.

## Future Catalysts

- Takeda plans to advance elritercept into a Phase 3 trial for anemia in myelofibrosis.

## Recent News
- 2026-08-03 20:01 EST — [Keros Therapeutics Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/KROS/keros-therapeutics-reports-second-quarter-2026-financial-results-ba3903e0) — Source: Keros Therapeutics
- 2026-07-30 20:01 EST — [Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda](https://biopharmsignal.com/news/KROS/keros-therapeutics-to-receive-development-milestone-payment-from-partner-takeda-a7403395) — Source: Keros Therapeutics
- 2026-06-25 20:01 EST — [Keros Therapeutics Appoints Anne Prener to its Board of Directors](https://biopharmsignal.com/news/KROS/keros-therapeutics-appoints-anne-prener-to-its-board-of-directors-7c27ad3b) — Source: Keros Therapeutics
- 2026-06-01 20:01 EST — [Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/KROS/keros-therapeutics-announces-participation-at-goldman-sachs-47th-annual-global-h-1adfec22) — Source: Keros Therapeutics
- 2026-05-14 12:00 EST — [Keros Therapeutics Reports Recent First Quarter 2026 Financial Results](https://biopharmsignal.com/news/KROS/keros-therapeutics-reports-recent-first-quarter-2026-financial-results-632f1ff6) — Source: Keros Therapeutics